Interleukin 18 (IL-18) and its binding protein (IL-18BP) are increased in patients with epilepsy suggesting low-grade systemic inflammation
| Autor: | Erik Taubøll, Thor Ueland, Ole A. Andreassen, Pål Aukrust, Sigrid Svalheim, Monika Mochol |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Lamotrigine Systemic inflammation Epileptogenesis Gastroenterology 03 medical and health sciences Epilepsy 0302 clinical medicine Internal medicine medicine Humans Inflammation business.industry Interleukin-18 VDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710 General Medicine Carbamazepine medicine.disease VDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710 Cross-Sectional Studies Neurology Intercellular Signaling Peptides and Proteins Biomarker (medicine) Interleukin 18 Neurology (clinical) Levetiracetam medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Popis: | Purpose - Proinflammatory cytokines seems to play a role in epileptogenesis independent of the underlying cause. The purpose of this study was to assess if IL-18 and its binding protein IL-18BP are related to epilepsy and could act as a predictive biomarker for epileptogenesis. Methods - In this cross-sectional study, circulating levels of IL-18 and IL-18BP were analysed in 119 epilepsy patients, and 80 healthy controls. Participants completed a questionnaire regarding epilepsy, use of drug(-s) and comorbidity. Results - Epilepsy patients had significantly higher serum levels of IL-18 (p = 0.003) and IL-18BP (p = 0.009) than healthy controls. The groups differed in sex, age and weight, however none of those variables were significantly correlated with IL-18 and IL-18BP in patients or controls. Weight was considered an important confounder in our study. Subgroup investigations revealed that in participants with BMI under 30 kg/m², serum IL-18 (p = 0.032) and IL-18BP (p = 0.029) remained significantly higher in patients than controls. Further analyses showed significantly higher concentration of IL-18 among participants using carbamazepine (CBZ) (p = 0.016) or lamotrigine (LTG) (p = 0.024), but not in those using levetiracetam (LEV) (p = 0.102) compared to controls. No associations were found between serum levels of IL-18 and IL-18BP and epilepsy duration, seizures type, or presence of seizures in the last six months. Conclusion - The study shows an elevation of IL-18 and IL-18BP serum levels in epilepsy patients. This result indicates the presence of a low-grade systemic inflammation involving IL-18 in epilepsy. Further investigations should explore the character and clinical impact of IL-18 as well its possible role as a biomarker for epilepsy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|